Gillian McGovern, Associate Editor

If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.

When different skin tones are considered in imaging systems, women will receive more equitable screening and care.

Asthma onset earlier in childhood may be linked to more severe difficulties that could extend to executive function abilities.

Potential solutions can include international funding, improved primary health care measures, and cost-effective screening methods.

These findings are significant in understanding interactions between glucagon-like peptide-1 medications and thyroid dysfunction because prior research has shown conflicting results.

Because these cells are present throughout the body, there may also be implications for other cancer types.

Postpartum depression (PPD) rates also had notable increases in those with class I and class II/III obesity.

This is the first oral liquid form of imatinib (Imkeldi; Shorla Oncology) to be approved to treat cancers.

Community health care workers help support both primary care and school settings by assisting with medication administration and communications with staff.

The guidelines were expanded to include the growing use of genetic testing within cancer prevention, screening, and treatment.

If approved, RAG-21 can offer improved outcomes in patients with amyotrophic lateral sclerosis (ALS), particularly those with aggressive subtypes.

Women aged 40 to 44 years at the time of natural menopause showed about a 30% decreased risk for asthma incidence.

The supplemental new drug application (sNDA) is based on results from a phase 3 trial that enrolled patients with metastatic hormone-sensitive prostate cancer (mHSPC).

The indication is for adults with previously treated unresectable or metastatic HER2+ (IHC+) biliary tract cancer (BTC) as detected by an FDA-approved test.

If patterns and trends were to continue, the authors predict that nationwide overweight and obesity prevalence in adults will surpass 80% by 2050.

Policies that focus on earlier diagnosis, treatment initiation, and expanded access to treatment can further improve treatment and health equity impacts.

Clinical trial analysis results studying VAD-44 in patients with hereditary hemorrhagic telangiectasia (HTT) will be presented at the 2024 American Society of Hematology Annual Meeting & Exposition.

Factors such as age, race, marital status, years since diagnosis, and out-of-pocket costs show significance as predictors of quality of life.

The indication is for adult and pediatric patients 1 year and older with a lysine methyltransferase 2A gene translocation.

The indication is for patients 12 and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

The intervention methods—annual asthma reviews, inhaler technique checks, and asthma management plans—were most effective when performed in the same visit.

The data also shows similar results for children with mothers who have pre-pregnancy body mass index outside of normal range.

Participants who completed the curriculum had answered 82% of the post-test correctly.

The study found that this patient population was about 25% more likely to have serious mental health issues after childbirth.

The analysis also found that the intervention methods could improve patients’ physical, cognitive, and emotional functioning.

Among this population, about 80% had not previously been diagnosed with asthma and over 30% were not using any asthma medications.

For up to 6 years, cognitive remediation and transcranial direct current stimulation slowed cognitive decline associated with major depressive disorder in remission and mild cognitive impairment.

The authors believe that improvements can be made to overlook the motherhood penalty and its associated pay gaps as well as changes to address workforce burnout.

Patients with low-grade intermediate-risk non-muscle-invasive bladder cancer who achieved a complete response rate after 3 months of UGN-102 treatment had an 82.3% duration of response at 12 months.

The findings show robust connections between symptoms, with variations in depression scores directly or indirectly influence fatigue and other symptoms.